NCT01216982View on ClinicalTrials.gov

Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders

PHASE2UnknownINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

June 30, 2011

Conditions
Mood DisordersDepressionCombat DisordersStress Disorders
Interventions
DRUG

Lovaza, omega-3 fatty acid ethyl ester

Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day

DRUG

Placebo, visually identical to Lovaza

Three 1g corn oil capsules/day for three months

Trial Locations (1)

09378

US Military Base, Camp Taji

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

United States Department of Defense

FED

NCT01216982 - Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders | Biotech Hunter | Biotech Hunter